Logo image of AKTX

AKARI THERAPEUTICS PLC-ADR (AKTX) Stock Overview

NASDAQ:AKTX - US00972G2075 - ADR

0.655 USD
-0.04 (-6.42%)
Last: 9/3/2025, 8:00:00 PM
0.6449 USD
-0.01 (-1.54%)
After Hours: 9/3/2025, 8:00:00 PM

AKTX Key Statistics, Chart & Performance

Key Statistics
52 Week High3.85
52 Week Low0.57
Market Cap21.36M
Shares32.61M
Float214.50K
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.58
PEN/A
Fwd PEN/A
Earnings (Next)11-17 2025-11-17
IPO01-31 2014-01-31
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


AKTX short term performance overview.The bars show the price performance of AKTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

AKTX long term performance overview.The bars show the price performance of AKTX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AKTX is 0.655 USD. In the past month the price decreased by -34.3%. In the past year, price decreased by -80.27%.

AKARI THERAPEUTICS PLC-ADR / AKTX Daily stock chart

AKTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.01 374.26B
AMGN AMGEN INC 13.01 152.81B
GILD GILEAD SCIENCES INC 14.6 140.20B
VRTX VERTEX PHARMACEUTICALS INC 23.41 101.69B
REGN REGENERON PHARMACEUTICALS 12.35 59.76B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.65B
ARGX ARGENX SE - ADR 77.89 44.19B
ONC BEONE MEDICINES LTD-ADR 6.78 39.97B
INSM INSMED INC N/A 30.33B
BNTX BIONTECH SE-ADR N/A 24.14B
NTRA NATERA INC N/A 22.99B
BIIB BIOGEN INC 8.85 20.76B

About AKTX

Company Profile

AKTX logo image Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-01-31. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. The company is pursuing research on two additional novel payloads, such as PH5 and PH6. The company also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Company Info

AKARI THERAPEUTICS PLC-ADR

22 Boston Wharf Road, Fl 7

Boston MASSACHUSETTS W1G 9RT US

CEO: Clive Richardson

Employees: 9

AKTX Company Website

AKTX Investor Relations

Phone: 16463500702

AKARI THERAPEUTICS PLC-ADR / AKTX FAQ

What is the stock price of AKARI THERAPEUTICS PLC-ADR today?

The current stock price of AKTX is 0.655 USD. The price decreased by -6.42% in the last trading session.


What is the ticker symbol for AKARI THERAPEUTICS PLC-ADR stock?

The exchange symbol of AKARI THERAPEUTICS PLC-ADR is AKTX and it is listed on the Nasdaq exchange.


On which exchange is AKTX stock listed?

AKTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AKARI THERAPEUTICS PLC-ADR stock?

8 analysts have analysed AKTX and the average price target is 6.12 USD. This implies a price increase of 834.35% is expected in the next year compared to the current price of 0.655. Check the AKARI THERAPEUTICS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AKARI THERAPEUTICS PLC-ADR worth?

AKARI THERAPEUTICS PLC-ADR (AKTX) has a market capitalization of 21.36M USD. This makes AKTX a Nano Cap stock.


How many employees does AKARI THERAPEUTICS PLC-ADR have?

AKARI THERAPEUTICS PLC-ADR (AKTX) currently has 9 employees.


What are the support and resistance levels for AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

AKARI THERAPEUTICS PLC-ADR (AKTX) has a resistance level at 0.93. Check the full technical report for a detailed analysis of AKTX support and resistance levels.


Should I buy AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AKARI THERAPEUTICS PLC-ADR (AKTX) stock pay dividends?

AKTX does not pay a dividend.


When does AKARI THERAPEUTICS PLC-ADR (AKTX) report earnings?

AKARI THERAPEUTICS PLC-ADR (AKTX) will report earnings on 2025-11-17.


What is the Price/Earnings (PE) ratio of AKARI THERAPEUTICS PLC-ADR (AKTX)?

AKARI THERAPEUTICS PLC-ADR (AKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).


What is the Short Interest ratio of AKARI THERAPEUTICS PLC-ADR (AKTX) stock?

The outstanding short interest for AKARI THERAPEUTICS PLC-ADR (AKTX) is 35.86% of its float. Check the ownership tab for more information on the AKTX short interest.


AKTX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

AKTX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to AKTX. AKTX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AKTX Financial Highlights

Over the last trailing twelve months AKTX reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 20% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.09%
ROE -47.91%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%100%
Sales Q2Q%N/A
EPS 1Y (TTM)20%
Revenue 1Y (TTM)N/A

AKTX Forecast & Estimates

8 analysts have analysed AKTX and the average price target is 6.12 USD. This implies a price increase of 834.35% is expected in the next year compared to the current price of 0.655.


Analysts
Analysts82.5
Price Target6.12 (834.35%)
EPS Next Y86.32%
Revenue Next YearN/A

AKTX Ownership

Ownership
Inst Owners0.91%
Ins Owners34.7%
Short Float %35.86%
Short Ratio2.31